Letters Adverse drug reactions

Authors’ reply to MacDonald and Etminan

BMJ 2014; 349 doi: https://doi.org/10.1136/bmj.g5523 (Published 17 September 2014) Cite this as: BMJ 2014;349:g5523
  1. Andrew Grey, associate professor1,
  2. Kirin Tan, medical student1,
  3. Keith J Petrie, professor2,
  4. Kate Faasse, postdoctoral fellow2,
  5. Mark J Bolland, associate professor1
  1. 1Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
  2. 2Department of Psychological Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
  1. a.grey{at}auckland.ac.nz

MacDonald discusses the importance of the summary of product characteristics, a document prepared by companies seeking marketing approval for their drugs, to presentation of information about adverse drug reactions by a regulatory authority.1 2 The inclusion in this summary of any adverse reaction …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe